4 июн. 2022 г. · In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained ...

11 дек. 2023 г. · In participants with obesity or overweight, withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and ...

8 июл. 2024 г. · Although most adults with overweight or obesity experienced 5% or greater weight loss with treatment, the benefit was greater with tirzepatide.

6 дней назад · Tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period.

8 нояб. 2023 г. · The US Food and Drug Administration approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity.

15 окт. 2023 г. · Tirzepatide provided substantial additional reduction in body weight in participants who had achieved ≥5.0% weight reduction with intensive lifestyle ...

Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 ...

2 янв. 2024 г. · In participants with obesity or overweight, withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and ...

21 июн. 2024 г. · Treatment with tirzepatide has led to significant reductions in excess body weight, improvements in blood pressure, and reductions in markers of ...

26 июн. 2023 г. · In SURMOUNT-2, adults with a BMI 27 kg/m2 or higher and type 2 diabetes treated with tirzepatide for 72 weeks had a mean bodyweight reduction of ...